FASTQ
SRA
Title | Illumina HiSeq 2500 paired end sequencing; Emergence of resistance to tyrosine kinase inhibitors in non-small cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib |
Design Description | Emergence of resistance to tyrosine kinase inhibitors in non-small cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib |
Organism | Homo sapiens |
Name | CR5_p |
Strategy | WXS |
Source | GENOMIC |
Selection | cDNA |
Layout | PAIRED |
Orientation | |
Nominal Length | 150 |
Nominal Sdev | 20 |
Construction Protocol | The crizotinib-resistant H2228 cell lines (H2228-CR) were generated in house and derived from EML4-ALK H2228 xenograft tumours, which acquired resistance to crizotinib in vivo after continuous crizotinib monotherapy. DNA isolation performed by GATC Biotech Exome enrichment performed using Agilent SureSelect Human All Exon v5 |
Platform | ILLUMINA |
Instrument Model | Illumina HiSeq 2500 |
Base Calls | |
---|---|
Sequence Space | |
Base Caller |
Number of Reads per Spots | 0 |
Spot Length | 202 |
Read Index 0 | |
---|---|
Read Label | |
Read Class | Application Read |
Read Type | Forward |
Base Coord | 1 |
Read Index 1 | |
Read Label | |
Read Class | Application Read |
Read Type | Reverse |
Base Coord | 102 |